FDA Approves First Drug for Myelofibrosis With Thrombocytopenia

Pacritinib is indicated specifically for patients with myelofibrosis and very low platelet counts, which develop in about one third of patients.
FDA Approvals

source https://www.medscape.com/viewarticle/969389?src=rss

Comments

Popular posts from this blog

Student Nurses Who Refuse Vaccination Struggle to Complete Degrees

The Clinical Characteristics of Fractures in Pediatric Patients Exposed to Proton Pump Inhibitors